Abstract:In psychiatric disorders, common and rare genetic variants cause widespread dysfunction of cells and their interactions, especially in the prefrontal cortex, giving rise to psychiatric symptoms. To better understand these processes, we traced the effects of common and rare genetics, and cumulative disease risk scores, to their molecular footprints in human cortical single-cell types. We demonstrated that examining gene expression at single-exon resolution is crucial for understanding the cortical dysregulation associated with diagnosis and genetic risk derived from common variants. We then used disease risk scores to identify a core set of genes that serve as a footprint of common and rare variants in the cortex. Pathways enriched in these genes included dopamine regulation, circadian entrainment, and hormone regulation. Single-nuclei-RNA-sequencing pinpointed these enriched genes to excitatory cortical neurons. This study highlights the importance of studying sub-gene-level genetic architecture to classify psychiatric disorders based on biology rather than symptomatology, to identify novel targets for treatment development. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233860/pdf/jove-20-914.pdf> ### Funding Statement The Victorian Brain Bank tissue collection was supported by the National Health and Medical Research Council (NHMRC; Australia; grant number 566967) and the Cooperative Research Centre (CRC) for Mental Health and the Operational Infrastructure Support from the Victorian State Government. The New South Wales Brain Tissue Resource Centre at the University of Sydney was supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Dr Knauer-Arloth was supported by the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #28063). Dr Matosin was supported by an Al and Val Rosenstrauss Fellowship from the Rebecca L Cooper Medical Research Foundation and grants from the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #26486) and the Rebecca L. Cooper Medical Research Foundation (#PG2020645). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the Victorian Institute of Forensic Medicine gave ethical approval for this work. Ethics committee/IRB of the Human Ethics Committee of Melbourne Health gave ethical approval for this work. Ethics committee/IRB of the Central Institute of Mental Health Mannheim gave ethical approval for this work. Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the Human Research Ethics Committees at the University of Wollongong gave ethical approval for this work. Ethics committee/IRB of the Ludwig-Maximilians-Universitaet Muenchen gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Expression data of dataset 1 in the present study are available online at GEO (GSE208338) and the genotypes are available upon reasonable request to the authors. Genes altered by rare coding variants from SCHEMA exome sequencing results in dataset 2 are available online at https://schema.broadinstitute.org/downloads. snRNA-seq data of dataset 3 in the present study are available online at GEO (GSE205642). <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205642> <https://drive.google.com/drive/folders/1JRyThjCwb7JFE6LdQQiAHwXQZFIO2o0V?usp=sharing> <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208338> <https://schema.broadinstitute.org/downloads>

Replication of restless legs syndrome loci in three European populations

Genomic Analysis Identifies Risk Factors in Restless Legs Syndrome

Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction

Association of BTBD9 and MAP2K5/SKOR1 with Restless Legs Syndrome in Chinese Population.

Genetic Association Study of Restless Legs Syndrome in Chinese Population.

A patient-enriched MEIS1 coding variant causes a restless legs syndrome-like phenotype in mice

Identification of Causal Genes and Potential Drug Targets for Restless Legs Syndrome: A Comprehensive Mendelian Randomization Study

LAG3/CD4 Genes Variants and the Risk for Restless Legs Syndrome

Intronic elements associated with insomnia and restless legs syndrome exhibit cell-type-specific epigenetic features contributing to MEIS1 regulation

SNCA-Rep1 polymorphism correlates with susceptibility and iron deficiency in restless legs syndrome

A Haplotype of MAP2K5/SKOR1 Was Associated with Essential Tremor in Chinese Population

Assessment of heterogeneity between European Populations: a Baltic and Danish replication case-control study of SNPs from a recent European ulcerative colitis genome wide association study

Variant-risk-exon interplay impacts circadian rhythm and dopamine signaling pathway in severe psychiatric disorders

Evidence for Contribution of Common Genetic Variants Within Chromosome 8P21.2-8P21.1 to Restricted and Repetitive Behaviors in Autism Spectrum Disorders

Patients with restless legs syndrome exhibit reduced serum colony-stimulating factor-1, humanin-like 3 and 10 levels

Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases

Multivariable Mendelian Randomization Analysis Reveals the Protective Effect of Restless Legs Syndrome against Lower Limb Venous Diseases and Pulmonary Embolism

0026 GENETIC LOCI IN PERIODIC HYPERSOMNIA/KLEINE-LEVIN SYNDROME TYPE

Shared genetic architecture and causal pathways between attention deficit hyperactivity disorder and restless legs syndrome

Variant of EOMES Associated with Increasing Risk in Chinese Patients with Relapsing-remitting Multiple Sclerosis

Further investigation in europeans of susceptibility variants for polycystic ovary syndrome discovered in genome-wide association studies of Chinese individuals